AlphaCentric Advisors’s Fulcrum Therapeutics FULC Stock Holding History

AlphaCentric Advisors’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$504K	Buy	+28,500	New	+$565K	0.15%	63

Other funds holding FULC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AlphaCentric Advisors's FULC Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in Fulcrum Therapeutics (FULC) in Q4 2021: 28,500 shares worth $504K. The stake represents 0.15% of the portfolio and ranks #63 among its holdings.

110 funds tracked by Wall St. Rank hold FULC as of Q4 2021.

AlphaCentric Advisors held 28,500 shares of Fulcrum Therapeutics worth $504K as of Q4 2021.
Fulcrum Therapeutics was a new AlphaCentric Advisors position in Q4 2021.
Fulcrum Therapeutics made up 0.15% of AlphaCentric Advisors's portfolio in Q4 2021, its #63 holding.
110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.